Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,943 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Context 2 Clear all

Conditions: Nulliparous Women Who Scheduled for Labor Induction, Pregnancy
Interventions: Sequential Cervical Ripening, Inpatient Combined Cervical Ripening; Combination Product
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Mass Casualty Incident, Dehydration
Interventions: hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glycogen Storage Disease Type Ia
Interventions: No Intervention; Other
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 2 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 9
States / cities: Orange, California • Denver, Colorado • Hartford, Connecticut + 6 more

Conditions: Multiple Myeloma
Interventions: BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF; Drug
Lead sponsor: BioLineRx, Ltd.; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: NT219; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 2
States / cities: Aurora, Colorado • Highlands Ranch, Colorado

Conditions: PreDiabetes
Interventions: Whole Prediabetes Diet Intervention; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 25 Years to 59 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 1 Diabetes Mellitus
Interventions: CoYoT1 Care, Standard Care; Behavioral · Other
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 16 Years to 25 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: CNS Cancer, Head and Neck Cancer, GI Cancer, Gynecologic Cancer, Prostate Cancer, Thoracic Cancer, Breast Cancer
Interventions: Pencil Beam Scanning Proton Therapy; Radiation
Lead sponsor: The New York Proton Center; Other
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Myeloid Leukemia
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 143
States / cities: Muscle Shoals, Alabama • Phoenix, Arizona • Sedona, Arizona + 129 more

Conditions: Hearing Loss, Bilateral
Interventions: Parent-Mediated Intervention (PMI); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 5 Years to 8 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Bell Palsy
Interventions: Electrical stimulation device (tens unit); Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pancreatic Adenocarcinoma, Liver Metastases
Interventions: Floxuridine (FUDR), Hepatic Artery Infusion Pump, Heparinized Saline; Drug · Device
Lead sponsor: Corewell Health West; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Insomnia Disorder
Interventions: Cognitive Behavioral Therapy for Insomnia, Passive Body Heating (PBH); Behavioral · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Head and Neck Cancer, Survivorship, Caregiver Burden, Head and Neck Neoplasms
Interventions: Survivorship Needs Assessment Planning (SNAP) tool; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: High-risk Muscle Invasive Urothelial Carcinoma
Interventions: Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab, Enfortumab vedotin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 915 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 19
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more

Conditions: Overweight and Obesity
Interventions: Experimental: Web-based only (WO) weight intervention, Experimental: WO plus peer-led discussion board (WD), Experimental: WO & professional email counseling (WE); Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 40 Years to 69 Years · Female only
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Memory Loss (Excluding Dementia), Healthy Lifestyle, Risk Reduction Behavior
Interventions: My Healthy Brain 1, My Healthy Brain 2; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma
Interventions: Tislelizumab, Capecitabine, 5-fluorouracil (5-FU), Oxaliplatin, Leucovorin; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 9
States / cities: Bullhead City, Arizona • Cerritos, California • Los Angeles, California + 6 more

Conditions: Major Depressive Disorder
Interventions: Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC); Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 30 Years to 60 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Stage II Rectal Cancer, Organ Preservation, Non-operative Treatment, Rectal Cancer (Stage III), Rectal Cancer Patients
Interventions: Complete responders and Non-complete responders, Chemoradiation + EBRT Boost, Chemoradiation + HDRBT Boost; Procedure · Radiation
Lead sponsor: Sir Mortimer B. Davis - Jewish General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Behavior and Behavior Mechanisms
Interventions: Not listed
Lead sponsor: New York University; Other
Eligibility: 17 Years to 19 Years
Enrollment: 2,960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid Use Disorder
Interventions: Extended-release Buprenorphine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Abdominal Aortic Aneurysm
Interventions: 1 million MSCs/kg, 3 million MSCs/kg, Placebo; Biological · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Violence in Adolescence, Substance Use, Avoidance of Healthcare
Interventions: BrotherlyACT, BrotherlyACT Waitlist Control Group (WCG); Behavioral · Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 15 Years to 24 Years · Male only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Ripening Approaches for Prompt Induction and Delivery - Sequential Versus Concurrent Dilapan-S and Misoprostol to Achieve Vaginal Delivery (RAPID-DS)

Recombinant Hyaluronidase in Out-of-Hospital Setting: The EASI Access Trial

Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Whole Prediabetes: A Family-Centered Whole Foods Diet in Adults With Prediabetes and Their Offspring

CoYoT1 to California

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Long-Term Outcomes of Early Communication Intervention for Deaf/Hard of Hearing Toddlers

Electrical Stimulation to Promote Recovery in Bells Palsy

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

Optimizing an Integrated Mind and Body Treatment for Insomnia: The SLEEPS Study

The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

Web-Based Weight Loss & Weight Maintenance Intervention for Older Rural Women, Also Known as Women Weigh-in for Wellness

Brain Health Program for Older Adults With Subjective Cognitive Decline

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

African American Depression Intervention Trial (AADI)

Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery

Couple & Family Contexts

Extended-release Buprenorphine as a Novel Low-dose Induction Strategy

Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms

BrotherlyACT: A Tech-Enhanced Violence and Substance Use Intervention for Black Boys and Young Men